Unicycive Therapeutics, Inc. Quarterly report [Sections 13 or 15(d)]

Cash, Cash Equivalents, and Marketable Securities (Tables)

6 Months Ended

Jun. 30, 2026

The following table summarizes the Company’s investments as of June 30, 2026 (in thousands):

	Amortized Cost Basis		Unrealized Gains		Unrealized Losses			Estimated Fair Value

Cash	$	44,185	$	-	$	-		$	44,185
Investments in corporate bonds		17,263		-		(23	)		17,240
Total cash, cash equivalents and investments in marketable securities	$	61,448	$	-	$	(23	)	$	61,425

The following table summarizes the Company’s investments as of December 31, 2025 (in thousands):

	Amortized Cost Basis		Unrealized Gains		Unrealized Losses			Estimated Fair Value

Cash	$	24,172	$	-	$	-		$	24,172
U.S. Treasury Bills		3,449		-		-			3,449
Money Market		1,577							1,577
Investments in corporate bonds		12,072		-		(1	)		12,071
Total cash, cash equivalents and investments in marketable securities	$	41,270	$	-	$	(1	)	$	41,269